Classics in Chemical Neuroscience: Levodopa
Levodopa was the first and most successful breakthrough in the treatment of Parkinson’s disease (PD). It is estimated that PD affects approximately 1 million people in the United States alone. Although PD was discovered in 1817, prior to levodopa’s discovery there was not an effective treatment for...
Gespeichert in:
| Veröffentlicht in: | ACS chemical neuroscience 2014-12, Vol.5 (12), p.1192-1197 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1197 |
|---|---|
| container_issue | 12 |
| container_start_page | 1192 |
| container_title | ACS chemical neuroscience |
| container_volume | 5 |
| creator | Whitfield, A. Connor Moore, Ben T Daniels, R. Nathan |
| description | Levodopa was the first and most successful breakthrough in the treatment of Parkinson’s disease (PD). It is estimated that PD affects approximately 1 million people in the United States alone. Although PD was discovered in 1817, prior to levodopa’s discovery there was not an effective treatment for managing its symptoms. In 1961, Hornykiewicz pioneered the use of levodopa to enhance dopamine levels in the striatum, significantly improving symptoms in many patients. With the addition of carbidopa in 1974, the frequency of gastrointestinal adverse drug reactions (ADRs) was significantly reduced, leading to the modern treatment of PD. Although levodopa treatment is more than 50 years old, it remains the “gold standard” for PD treatment. This Review describes in detail the synthesis, metabolism, pharmacology, ADRs, and importance of levodopa therapy to neuroscience in the past and present. |
| doi_str_mv | 10.1021/cn5001759 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1637996906</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1637996906</sourcerecordid><originalsourceid>FETCH-LOGICAL-a381t-52abfc066349112ed41ae0f9af38c3790d850e3ed17285897c75ed63bfe2fb733</originalsourceid><addsrcrecordid>eNptkEtLAzEUhYMotlYX_gGZjaDIaG7SvNzJ4AuKbnQdMpkbnDKPOnEE_72R1uLC1b2Lj49zDiHHQC-BMrjynaAUlDA7ZApmrnMFhu_--SfkIMYlpdJQLffJhAmmKFMwJRdF42KsfczqLivesK29a7InHIc--ho7j9fZAj_7ql-5Q7IXXBPxaHNn5PXu9qV4yBfP94_FzSJ3XMNHLpgrg6dS8rkBYFjNwSENxgWuPVeGVlpQ5FiBYlpoo7wSWEleBmShVJzPyNnauxr69xHjh23r6LFpXIf9GC3IZDGpi0zo-Rr1KW8cMNjVULdu-LJA7c82drtNYk822rFssdqSv2Mk4HQNOB_tsh-HLrX8R_QNvg9oTQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1637996906</pqid></control><display><type>article</type><title>Classics in Chemical Neuroscience: Levodopa</title><source>ACS Publications</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Whitfield, A. Connor ; Moore, Ben T ; Daniels, R. Nathan</creator><creatorcontrib>Whitfield, A. Connor ; Moore, Ben T ; Daniels, R. Nathan</creatorcontrib><description>Levodopa was the first and most successful breakthrough in the treatment of Parkinson’s disease (PD). It is estimated that PD affects approximately 1 million people in the United States alone. Although PD was discovered in 1817, prior to levodopa’s discovery there was not an effective treatment for managing its symptoms. In 1961, Hornykiewicz pioneered the use of levodopa to enhance dopamine levels in the striatum, significantly improving symptoms in many patients. With the addition of carbidopa in 1974, the frequency of gastrointestinal adverse drug reactions (ADRs) was significantly reduced, leading to the modern treatment of PD. Although levodopa treatment is more than 50 years old, it remains the “gold standard” for PD treatment. This Review describes in detail the synthesis, metabolism, pharmacology, ADRs, and importance of levodopa therapy to neuroscience in the past and present.</description><identifier>ISSN: 1948-7193</identifier><identifier>EISSN: 1948-7193</identifier><identifier>DOI: 10.1021/cn5001759</identifier><identifier>PMID: 25270271</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><subject>Animals ; Antiparkinson Agents - chemical synthesis ; Antiparkinson Agents - chemistry ; Antiparkinson Agents - classification ; Antiparkinson Agents - therapeutic use ; History, 19th Century ; History, 20th Century ; Humans ; Levodopa - chemical synthesis ; Levodopa - chemistry ; Levodopa - classification ; Levodopa - therapeutic use ; Neurosciences - history ; Parkinson Disease - drug therapy</subject><ispartof>ACS chemical neuroscience, 2014-12, Vol.5 (12), p.1192-1197</ispartof><rights>Copyright © 2014 American Chemical Society</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a381t-52abfc066349112ed41ae0f9af38c3790d850e3ed17285897c75ed63bfe2fb733</citedby><cites>FETCH-LOGICAL-a381t-52abfc066349112ed41ae0f9af38c3790d850e3ed17285897c75ed63bfe2fb733</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/cn5001759$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/cn5001759$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>314,776,780,2752,27053,27901,27902,56713,56763</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25270271$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Whitfield, A. Connor</creatorcontrib><creatorcontrib>Moore, Ben T</creatorcontrib><creatorcontrib>Daniels, R. Nathan</creatorcontrib><title>Classics in Chemical Neuroscience: Levodopa</title><title>ACS chemical neuroscience</title><addtitle>ACS Chem. Neurosci</addtitle><description>Levodopa was the first and most successful breakthrough in the treatment of Parkinson’s disease (PD). It is estimated that PD affects approximately 1 million people in the United States alone. Although PD was discovered in 1817, prior to levodopa’s discovery there was not an effective treatment for managing its symptoms. In 1961, Hornykiewicz pioneered the use of levodopa to enhance dopamine levels in the striatum, significantly improving symptoms in many patients. With the addition of carbidopa in 1974, the frequency of gastrointestinal adverse drug reactions (ADRs) was significantly reduced, leading to the modern treatment of PD. Although levodopa treatment is more than 50 years old, it remains the “gold standard” for PD treatment. This Review describes in detail the synthesis, metabolism, pharmacology, ADRs, and importance of levodopa therapy to neuroscience in the past and present.</description><subject>Animals</subject><subject>Antiparkinson Agents - chemical synthesis</subject><subject>Antiparkinson Agents - chemistry</subject><subject>Antiparkinson Agents - classification</subject><subject>Antiparkinson Agents - therapeutic use</subject><subject>History, 19th Century</subject><subject>History, 20th Century</subject><subject>Humans</subject><subject>Levodopa - chemical synthesis</subject><subject>Levodopa - chemistry</subject><subject>Levodopa - classification</subject><subject>Levodopa - therapeutic use</subject><subject>Neurosciences - history</subject><subject>Parkinson Disease - drug therapy</subject><issn>1948-7193</issn><issn>1948-7193</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkEtLAzEUhYMotlYX_gGZjaDIaG7SvNzJ4AuKbnQdMpkbnDKPOnEE_72R1uLC1b2Lj49zDiHHQC-BMrjynaAUlDA7ZApmrnMFhu_--SfkIMYlpdJQLffJhAmmKFMwJRdF42KsfczqLivesK29a7InHIc--ho7j9fZAj_7ql-5Q7IXXBPxaHNn5PXu9qV4yBfP94_FzSJ3XMNHLpgrg6dS8rkBYFjNwSENxgWuPVeGVlpQ5FiBYlpoo7wSWEleBmShVJzPyNnauxr69xHjh23r6LFpXIf9GC3IZDGpi0zo-Rr1KW8cMNjVULdu-LJA7c82drtNYk822rFssdqSv2Mk4HQNOB_tsh-HLrX8R_QNvg9oTQ</recordid><startdate>20141217</startdate><enddate>20141217</enddate><creator>Whitfield, A. Connor</creator><creator>Moore, Ben T</creator><creator>Daniels, R. Nathan</creator><general>American Chemical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20141217</creationdate><title>Classics in Chemical Neuroscience: Levodopa</title><author>Whitfield, A. Connor ; Moore, Ben T ; Daniels, R. Nathan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a381t-52abfc066349112ed41ae0f9af38c3790d850e3ed17285897c75ed63bfe2fb733</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Animals</topic><topic>Antiparkinson Agents - chemical synthesis</topic><topic>Antiparkinson Agents - chemistry</topic><topic>Antiparkinson Agents - classification</topic><topic>Antiparkinson Agents - therapeutic use</topic><topic>History, 19th Century</topic><topic>History, 20th Century</topic><topic>Humans</topic><topic>Levodopa - chemical synthesis</topic><topic>Levodopa - chemistry</topic><topic>Levodopa - classification</topic><topic>Levodopa - therapeutic use</topic><topic>Neurosciences - history</topic><topic>Parkinson Disease - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Whitfield, A. Connor</creatorcontrib><creatorcontrib>Moore, Ben T</creatorcontrib><creatorcontrib>Daniels, R. Nathan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>ACS chemical neuroscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Whitfield, A. Connor</au><au>Moore, Ben T</au><au>Daniels, R. Nathan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Classics in Chemical Neuroscience: Levodopa</atitle><jtitle>ACS chemical neuroscience</jtitle><addtitle>ACS Chem. Neurosci</addtitle><date>2014-12-17</date><risdate>2014</risdate><volume>5</volume><issue>12</issue><spage>1192</spage><epage>1197</epage><pages>1192-1197</pages><issn>1948-7193</issn><eissn>1948-7193</eissn><abstract>Levodopa was the first and most successful breakthrough in the treatment of Parkinson’s disease (PD). It is estimated that PD affects approximately 1 million people in the United States alone. Although PD was discovered in 1817, prior to levodopa’s discovery there was not an effective treatment for managing its symptoms. In 1961, Hornykiewicz pioneered the use of levodopa to enhance dopamine levels in the striatum, significantly improving symptoms in many patients. With the addition of carbidopa in 1974, the frequency of gastrointestinal adverse drug reactions (ADRs) was significantly reduced, leading to the modern treatment of PD. Although levodopa treatment is more than 50 years old, it remains the “gold standard” for PD treatment. This Review describes in detail the synthesis, metabolism, pharmacology, ADRs, and importance of levodopa therapy to neuroscience in the past and present.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>25270271</pmid><doi>10.1021/cn5001759</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1948-7193 |
| ispartof | ACS chemical neuroscience, 2014-12, Vol.5 (12), p.1192-1197 |
| issn | 1948-7193 1948-7193 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1637996906 |
| source | ACS Publications; MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Animals Antiparkinson Agents - chemical synthesis Antiparkinson Agents - chemistry Antiparkinson Agents - classification Antiparkinson Agents - therapeutic use History, 19th Century History, 20th Century Humans Levodopa - chemical synthesis Levodopa - chemistry Levodopa - classification Levodopa - therapeutic use Neurosciences - history Parkinson Disease - drug therapy |
| title | Classics in Chemical Neuroscience: Levodopa |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T13%3A07%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Classics%20in%20Chemical%20Neuroscience:%20Levodopa&rft.jtitle=ACS%20chemical%20neuroscience&rft.au=Whitfield,%20A.%20Connor&rft.date=2014-12-17&rft.volume=5&rft.issue=12&rft.spage=1192&rft.epage=1197&rft.pages=1192-1197&rft.issn=1948-7193&rft.eissn=1948-7193&rft_id=info:doi/10.1021/cn5001759&rft_dat=%3Cproquest_cross%3E1637996906%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1637996906&rft_id=info:pmid/25270271&rfr_iscdi=true |